Exane BNP Paribas analyst Nate Crossett upgrades Omega Healthcare Invts (NYSE:OHI) from Underperform to Neutral and announces $30 price target.
Exane BNP Paribas Upgrades Omega Healthcare Invts to Neutral, Announces $30 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.